Investment17 Nov 2025, 04:08 pm
AstraZeneca and Sun Pharma Partner to Expand Access to Hyperkalaemia Treatment in India
AI Summary
AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited have entered into a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement aims to further accelerate the availability of SZC, an innovative and highly effective treatment for Hyperkalaemia, to more patients across India. AstraZeneca will market SZC as Lokelma®, while Sun Pharma will promote and distribute the therapy as Gimliand®. The partnership is expected to significantly expand the reach of this vital therapy and help address the disease burden in India.
Key Highlights
- AstraZeneca and Sun Pharma partner to expand access to Hyperkalaemia treatment in India.
- Exclusive agreement to promote, market & distribute Sodium Zirconium Cyclosilicate (SZC) in India under different brand names.
- AstraZeneca to retain intellectual property rights and hold the Marketing Authorisation along with the import license of the molecule.
- Partnership aimed at addressing the growing challenge of Hyperkalaemia in India, particularly in patients with chronic kidney disease and heart failure.
- Sun Pharma, as India’s largest pharmaceutical company, to leverage its strong presence and field force to enhance availability and accessibility of SZC in India.